GH secretagogue
Sermorelin
GHRH(1-29) · GRF 1-29 · Geref
Cheapest, most accessible GH-optimization entry (telehealth under ~$130/mo); heavily marketed; the most legally secure compounded peptide.
Evidence
Bhuman trials
Status
Research-use-only — gray marketas of 2026-06
Approval
Not approved
Category
GH secretagogue
Route
Subcutaneous
Demand rank
#10 most-searched
01Dosing & Protocol
Typical · reference only
~200-300 mcg SC nightly (overlaps old adult dose); clinics 100-500 mcg/night, cycled
Titration
Start 100-200 mcg, reassess IGF-1 at 8-12 wks
Reconstitution — illustrative, not a recommendation
15 mg vial + 7.5 mL BAC = 2 mg/mL; 200 mcg = 10 U, 300 mcg = 15 U on U-100 (1 U = 20 mcg). NOTE: RxList prints '0.2-0.3 mcg' (typo for mg) - mcg/mg confusion = 1000x.
Reconstitution calculatorlive tool
10units
on a U-100 syringedraw to the 10 mark
Concentration2 mg/mL
Draw volume0.1 mL
Illustrative, not a recommendation. mg vs mcg confusion drives 5–1000× overdoses — always recompute for your own vial and syringe.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Most legally secure compounded peptide, but wellness use is OFF-LABEL and not FDA-approved for anti-aging.
Status
Research-use-only — gray market
503A bulks
Listed
Category 2
Distinct path - former approved drug (Geref, off-market 2008); 503A/503B compoundable
PCAC review
none scheduled
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows
Old, small human trials (1992-1999); none in healthy adults for anti-aging. Flagship 'Khorram 1997' result actually used a different analog ([Nle27]GHRH).
04Safety
Contraindications
- Active malignancy
- Pituitary/intracranial structural disease
- Pregnancyhard stop
- Untreated hypothyroidism
- Uncontrolled diabetes / proliferative retinopathy
Key interactions
- Glucocorticoids, somatostatin analogs, untreated hypothyroidism (blunt GH response)
- Antidiabetics (GH lowers insulin sensitivity)
Serious signals
- Outlier 'up to 2 mg/day' figure (~7-10x dose) has no safety basis - cap by IGF-1
Monitoring
IGF-1 within age/sex range; glucose/HbA1c.
05Related in GH secretagogue
06Sources
The primary sources behind this monograph — each opens the registry so you can verify the claim yourself. Last verified 2026-06-13.
SecondaryEmpower/Defy pharmacy guidanceCompounding-pharmacy protocol (secondary) · compounding protocolHow we source & verify — the full method →Beyond these primaries, every monograph is distilled from TrackurStack’s research dossier — 584 de-duplicated sources across 4 research iterations, adversarially verified against primary sources.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high